Clinical Trials in Baltimore

Showing 5301-5320 of 17,842 trials

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

NCT01743807

This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive for Minimum Residual Disease (MRD).

Relapsed Acute Lymphoblastic LeukemiaRelapsed Acute Myelogenous Leukemia

Therapeutic Advances in Childhood Leukemia Consortium4 participantsStarted Mar 2014

Los Angeles, California, United States • Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCT03220035

This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more

National Cancer Institute (NCI)4 participantsStarted Nov 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +113 more locations

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Find Trials by Condition in Baltimore

Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Novel Experimental COVID-19 Therapies Affecting Host Response

Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

Intermediate-Size Expanded Access Protocol (EAP) for LP352

mHealth for Breast Cancer Survivors With Insomnia

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

The OPBC-07/microNAC Study

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

The Gilenya Pregnancy Registry

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia